# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient popu...
Cantor Fitzgerald analyst Josh Schimmer reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight.
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimat...
RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price t...